ALK and non-small cell lung carcinoma: In patients with nonsquamous NSCLC, the ORR was 50.0% (95% CI, 15.7%-84.3%) in patients with EGFR/ALK wild type versus 30.8% (95% CI, 9.1%-61.4%) in those with EGFR/ALK variations (P =0 .336) (Table 2).